Androgen-primed chemotherapy-Experimental confirmation of efficacy

R. J. Santen, Andrea Manni, H. F. English, D. Heitjan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A current hypothesis suggests that androgen administration prior to chemotherapy (androgen priming) may potentiate tumor cytotoxicity in prostate cancer. The Dunning R3327G rat prostatic tumor model was used to test this concept experimentally. Control groups without priming included (1) intact untreated, (2) castrate alone and (3) castrate + chemotherapy (cyclophosphamide, 30 mg/kg/day for 2 days with repeat cycle in 25 days-CTX). Two experimental groups received androgens, one before and one after chemotherapy. Treatment effect was monitored by quantitating tumor volume and animal survival. Control groups receiving castration and chemotherapy had a retardation of tumor growth and a prolongation of survival when compared to untreated animals. Androgen priming before but not after chemotherapy enhanced the degree of tumor suppression. With the androgen-priming protocol, all androgen-primed tumors had regressed, 3 6 tumors had disappeared and 3 were only palpable. At the same time point, tumors in all the other groups were actively growing and had volumes greater than the initial values (P < 0.01). Median survival was significantly prolonged in primed animals 191 vs 40 days for untreated animals and 150 days for the nonprimed castration + chemotherapy animals (P < 0.02). These findings have been repeated with several replicate experiments. These observations confirm the hypothesis that androgen priming can potentiate chemotherapy in an experimental system.

Original languageEnglish (US)
Pages (from-to)1115-1120
Number of pages6
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume37
Issue number6
DOIs
StatePublished - Dec 20 1990

Fingerprint

Chemotherapy
Androgens
Tumors
Drug Therapy
Animals
Neoplasms
Castration
Control Groups
Tumor Burden
Cyclophosphamide
Cytotoxicity
Prostatic Neoplasms
Rats
Growth

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Santen, R. J. ; Manni, Andrea ; English, H. F. ; Heitjan, D. / Androgen-primed chemotherapy-Experimental confirmation of efficacy. In: Journal of Steroid Biochemistry and Molecular Biology. 1990 ; Vol. 37, No. 6. pp. 1115-1120.
@article{4eca7d07374a48569533754f77754536,
title = "Androgen-primed chemotherapy-Experimental confirmation of efficacy",
abstract = "A current hypothesis suggests that androgen administration prior to chemotherapy (androgen priming) may potentiate tumor cytotoxicity in prostate cancer. The Dunning R3327G rat prostatic tumor model was used to test this concept experimentally. Control groups without priming included (1) intact untreated, (2) castrate alone and (3) castrate + chemotherapy (cyclophosphamide, 30 mg/kg/day for 2 days with repeat cycle in 25 days-CTX). Two experimental groups received androgens, one before and one after chemotherapy. Treatment effect was monitored by quantitating tumor volume and animal survival. Control groups receiving castration and chemotherapy had a retardation of tumor growth and a prolongation of survival when compared to untreated animals. Androgen priming before but not after chemotherapy enhanced the degree of tumor suppression. With the androgen-priming protocol, all androgen-primed tumors had regressed, 3 6 tumors had disappeared and 3 were only palpable. At the same time point, tumors in all the other groups were actively growing and had volumes greater than the initial values (P < 0.01). Median survival was significantly prolonged in primed animals 191 vs 40 days for untreated animals and 150 days for the nonprimed castration + chemotherapy animals (P < 0.02). These findings have been repeated with several replicate experiments. These observations confirm the hypothesis that androgen priming can potentiate chemotherapy in an experimental system.",
author = "Santen, {R. J.} and Andrea Manni and English, {H. F.} and D. Heitjan",
year = "1990",
month = "12",
day = "20",
doi = "10.1016/0960-0760(90)90475-Z",
language = "English (US)",
volume = "37",
pages = "1115--1120",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "6",

}

Androgen-primed chemotherapy-Experimental confirmation of efficacy. / Santen, R. J.; Manni, Andrea; English, H. F.; Heitjan, D.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 37, No. 6, 20.12.1990, p. 1115-1120.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Androgen-primed chemotherapy-Experimental confirmation of efficacy

AU - Santen, R. J.

AU - Manni, Andrea

AU - English, H. F.

AU - Heitjan, D.

PY - 1990/12/20

Y1 - 1990/12/20

N2 - A current hypothesis suggests that androgen administration prior to chemotherapy (androgen priming) may potentiate tumor cytotoxicity in prostate cancer. The Dunning R3327G rat prostatic tumor model was used to test this concept experimentally. Control groups without priming included (1) intact untreated, (2) castrate alone and (3) castrate + chemotherapy (cyclophosphamide, 30 mg/kg/day for 2 days with repeat cycle in 25 days-CTX). Two experimental groups received androgens, one before and one after chemotherapy. Treatment effect was monitored by quantitating tumor volume and animal survival. Control groups receiving castration and chemotherapy had a retardation of tumor growth and a prolongation of survival when compared to untreated animals. Androgen priming before but not after chemotherapy enhanced the degree of tumor suppression. With the androgen-priming protocol, all androgen-primed tumors had regressed, 3 6 tumors had disappeared and 3 were only palpable. At the same time point, tumors in all the other groups were actively growing and had volumes greater than the initial values (P < 0.01). Median survival was significantly prolonged in primed animals 191 vs 40 days for untreated animals and 150 days for the nonprimed castration + chemotherapy animals (P < 0.02). These findings have been repeated with several replicate experiments. These observations confirm the hypothesis that androgen priming can potentiate chemotherapy in an experimental system.

AB - A current hypothesis suggests that androgen administration prior to chemotherapy (androgen priming) may potentiate tumor cytotoxicity in prostate cancer. The Dunning R3327G rat prostatic tumor model was used to test this concept experimentally. Control groups without priming included (1) intact untreated, (2) castrate alone and (3) castrate + chemotherapy (cyclophosphamide, 30 mg/kg/day for 2 days with repeat cycle in 25 days-CTX). Two experimental groups received androgens, one before and one after chemotherapy. Treatment effect was monitored by quantitating tumor volume and animal survival. Control groups receiving castration and chemotherapy had a retardation of tumor growth and a prolongation of survival when compared to untreated animals. Androgen priming before but not after chemotherapy enhanced the degree of tumor suppression. With the androgen-priming protocol, all androgen-primed tumors had regressed, 3 6 tumors had disappeared and 3 were only palpable. At the same time point, tumors in all the other groups were actively growing and had volumes greater than the initial values (P < 0.01). Median survival was significantly prolonged in primed animals 191 vs 40 days for untreated animals and 150 days for the nonprimed castration + chemotherapy animals (P < 0.02). These findings have been repeated with several replicate experiments. These observations confirm the hypothesis that androgen priming can potentiate chemotherapy in an experimental system.

UR - http://www.scopus.com/inward/record.url?scp=0025640082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025640082&partnerID=8YFLogxK

U2 - 10.1016/0960-0760(90)90475-Z

DO - 10.1016/0960-0760(90)90475-Z

M3 - Article

C2 - 2285585

AN - SCOPUS:0025640082

VL - 37

SP - 1115

EP - 1120

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 6

ER -